The complaint alleges that Embecta Corp. provided false and misleading fiscal guidance for the second quarter and full fiscal year 2026. According to the filing, the company failed to disclose significant market headwinds, specifically within the pen needle sector, which undermined the reliability of its public projections. These omissions allegedly resulted in financial losses for shareholders once the market corrected for the actual company performance.

Schall Brown & Schwartz LLP is handling the case, which centers on alleged violations of the Securities Exchange Act of 1934. Investors interested in the litigation can contact firm partners Adam Rosen or David Schwartz at 310-301-3335 to discuss potential recovery options. While the class has not yet been certified, affected parties are encouraged to evaluate their legal standing before the mid-August deadline.